Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
ABBOTT PARK, Ill. — Abbott Laboratories filed a lawsuit against Watson Pharmaceuticals Inc. in Chicago, seeking a federal court injunction to immediately stop Watson’s advertising and trade practices regarding Abbott’s prescription thyroid drug Synthroid.
Abbott (ABT) said Tuesday it also asked the court to order Watson (WPI) to undertake an advertising campaign to correct “the deliberate misinformation it has created within the medical community.”
The Wall Street Journal has reported that the Food and Drug Administration issued regulatory notices to the maker of Synthroid early this month that the medicine has a “history of problems” and can’t be recognized as “safe and effective.”
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in